A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Lowdose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)

Project: Research

NMA HREC Reference Number: SVHM HREC ref 020/20
NMA SSA Reference Number: SSA/59714/MonH-2020-227895(v2)
Monash Health Reference: RES-20-0000-601X

Status	Finished
Effective start/end date	16/09/20 → 15/09/25

Project Details